Phase I clinical trial outcomes in 93 patients with brain metastases: The MD Anderson Cancer Center experience

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4110-4118

  Tsimberidou, Apostolia Maria ^a   Letourneau, Katherine ^a   Wen, Sijin ^a   Wheler, Jennifer ^a   Hong, David ^a   Naing, Aung ^a   Iskander, Nancy G ^a   Uehara, Cynthia ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CENTER; CHILD; CONFUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SEIZURE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959268009     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3095     Document Type: Article

References (19)

1. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77:655-61.
2. Chamberlain MC. Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother 2010;10:563-73.
3. Kamar FG, Posner JB. Brain metastases. Semin Neurol 2010;30:217-35.
4. Inoue R, Takahashi A, Takasugi S, Masumori N, Tsukamoto T, Hasegawa T. [Prognostic factors in patients with metastatic renal cell carcinoma]. Hinyokika Kiyo 2010;56:75-9.
5. Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol 2011;101:49-55.
6. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a Single-Institution Review. Cancer 2010;116:3084-92.
7. Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer 2010;70:174-9.
8. Carrubba CJ, Vitaz TW. Factors affecting the outcome after treatment for metastatic melanoma to the brain. Surg Neurol 2009;72:707-11.
9. Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, et al. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol 2004;66:313-25. (Pubitemid 38259814)
10. Ogawa K, Toita T, Sueyama H, Fuwa N, Kakinohana Y, Kamata M, et al. Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer 2002;94:759-64. (Pubitemid 34132305)
11. DiLuna ML, King JT Jr, Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer 2007;109:135-45. (Pubitemid 46127203)
12. Mickisch GH. Prognostic parameters for the management of advanced testis tumours. Curr Opin Urol 2000;10:465-71.
13. Shinoda J, Sakai N, Yano H, Hattori T, Ohkuma A, Sakaguchi H. Prognostic factors and therapeutic problems of primary intracranial choriocarcinoma/germ- cell tumors with high levels of HCG. J Neurooncol 2004;66:225-40. (Pubitemid 38258379)
14. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, et al. Survival of patients in a phase 1 clinic: the M. D. Anderson Cancer Center experience. Cancer 2009;115:1091-9.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. Fairclough DL, Cella DF. Eastern Cooperative Oncology Group (ECOG). J Natl Cancer Inst Monogr 1996:73-5.
17. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12. (Pubitemid 46630627)
18. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, NIH; 2009.
19. Markulin-Grgic L, Santek F. Treatment results in patients with brain metastases: Zagreb experience. J Clin Oncol 2010;Suppl; abstre 18132.